SCHEMBL23577953

SCHEMBL23577953

CCOC(=O)c1cc2c(cc1Br)oc(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ TP53 P04637 3/20 0.43
▸ MAOB P27338 2/20 0.43
▸ MAPT P10636 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HPGD P15428 1/20 0.41
▸ BAZ2B Q9UIF8 1/20 0.40
▸ BAZ2A Q9UIF9 1/20 0.40
▸ MIF P14174 1/20 0.40
▸ PFKFB3 Q16875 1/20 0.40
▸ MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183695 1.00 LMNA (0.47) LMNAKMT2AKDM4ENPSR1RXFP1
SCHEMBL24885167 0.85 ALDH1A1 (0.46) LMNAKMT2AKDM4ETP53HSD17B10
SCHEMBL30183917 0.84 LMNA (0.47) LMNAKDM4ETP53MAOBHSD17B10
SCHEMBL23577635 0.84 LMNA (0.47) LMNAKDM4ETP53MAOBHSD17B10
SCHEMBL23577857 0.80 KMT2A (0.56) LMNAKMT2AKDM4ENPSR1RXFP1
SCHEMBL30183958 0.80 KMT2A (0.56) LMNAKMT2AKDM4ENPSR1RXFP1
SCHEMBL30623227 0.79 KMT2A (0.55) LMNAKMT2AKDM4ENPSR1RXFP1
SCHEMBL26119918 0.79 KMT2A (0.55) LMNAKMT2AKDM4ENPSR1RXFP1
SCHEMBL23577752 0.76 LMNA (0.43) LMNAKMT2AKDM4ENPSR1TP53
SCHEMBL30184079 0.76 LMNA (0.43) LMNAKMT2AKDM4ENPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 — — EP disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 — — CN disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 — — US disclosed
CN-115605476-A Substituted tricyclic compounds 鲁宾有限公司(IN) 2023-01-13 — — CN disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 — — EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 LMNA 1729/4885KMT2A 4266/4885KDM4E 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback